Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When?
Background: COVID-19 imposes challenges in antibiotic decision-making due to similarities between bacterial pneumonia and moderate to severe COVID-19. We evaluated the effects of antibiotic therapy on the clinical outcomes of COVID-19 pneumonia patients and diagnostic accuracy of key inflammatory ma...
Main Authors: | Tat Ming Ng, Sean W. X. Ong, Audrey Y. X. Loo, Sock Hoon Tan, Hui Lin Tay, Min Yi Yap, David C. Lye, Tau Hong Lee, Barnaby E. Young |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/11/2/184 |
Similar Items
-
Antibiotic therapy in the treatment of COVID-19 pneumonia: who and when?
by: Ng, Tat Ming, et al.
Published: (2023) -
Antibiotic therapy for bacterial pneumonia
by: Hideo Kato
Published: (2024-07-01) -
Can clinical findings at admission allow withholding of antibiotics in patients hospitalized for community acquired pneumonia when a test for a respiratory virus is positive?
by: Ryan Ward, et al.
Published: (2025-01-01) -
Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies
by: Sandeep Nayar, et al.
Published: (2019-01-01) -
Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study
by: Gaëtan Gavazzi, et al.
Published: (2022-12-01)